公开(公告)号：WO2017139153A1

公开(公告)日：2017-08-17

申请号：PCT/US2017/016058

申请日：2017-02-01

Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Inventor： PINTER, Abraham ,  PATEL, Deendayal ,  CHOUDHARY, Alok

IPC: G01N33/569 ,  C07K16/12 ,  C07K16/28 ,  A61K39/395 ,  A61K39/02 ,  A61K39/04

CPC classification number: G01N33/5695 ,  C07K16/1289 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/92 ,  G01N2333/35 ,  G01N2400/02 ,  G01N2800/44

Abstract: The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

Abstract translation: 本发明广泛地提供了不同的组合物，试剂盒，载体和方法，包括针对在脂阿拉伯甘露聚糖（LAM）和磷脂酰肌醇 - 甘露糖苷6（PIM6）中发现的表位的单克隆抗体，用于诊断和治疗 结核分枝杆菌感染。

公开(公告)号：WO2017042819A1

公开(公告)日：2017-03-16

申请号：PCT/IL2016/051006

申请日：2016-09-11

Applicant: MOLECULAR DETECTION ISRAEL LTD.

Inventor： GASSEL, Aryeh ,  SUISSA, Yaron ,  GASSEL, Raphael ,  TAL, Maoz ,  MAN, Iaacov ,  ARIELI, Boaz

IPC: C12Q1/04 ,  C12Q1/24 ,  C12N1/00 ,  G01N33/49 ,  C12Q1/37

CPC classification number: C12N1/00 ,  C12Q1/04 ,  C12Q1/24 ,  G01N2800/44

Abstract: This disclosure relates to methods for isolating bacterial cells, fungal cells, and single-celled parasites present in a blood sample containing higher eukaryotic cells; particularly wherein the microorganisms are present at a concentration significantly lower than the eukaryotic cells in the sample.

Abstract translation: 本公开涉及分离存在于含有较高真核细胞的血液样品中的细菌细胞，真菌细胞和单细胞寄生虫的方法; 特别是其中微生物以显着低于样品中的真核细胞的浓度存在。

公开(公告)号：WO2015097061A1

公开(公告)日：2015-07-02

申请号：PCT/EP2014/078470

申请日：2014-12-18

Applicant: BRUKER DALTONIK GMBH

Inventor： BIERBAUM, Gabriele ,  SZEKAT, Christiane ,  ALSABTI, Nahed ,  JOSTEN, Michaele ,  REIF, Marion

IPC: G01N33/68

CPC classification number: C12Q1/14 ,  G01N33/6851 ,  G01N2333/31 ,  G01N2800/44

Abstract: The invention provides a method for identifying methicillin resistant Staphylococcus aureus (MRSA) in a bacterial sample comprising the steps: classifying bacteria in the sample as Staphylococcus aureus (SA) and determining the presence or absence of the phenol soluble modulin peptide or a variant thereof wherein the presence of the PSM-mec peptide or variant thereof indicates methicillin resistant Staphylococcus aureus. The variant is preferably the formylated version of the PSM-mec peptide having a mass to charge ratio of 2415 in a singly protonated state.

Abstract translation: 本发明提供了一种在细菌样品中鉴定耐甲氧西林金黄色葡萄球菌（MRSA）的方法，包括以下步骤：将样品中的细菌分类为金黄色葡萄球菌（SA），并测定苯酚可溶性调节素肽或其变体的存在或不存在，其中 PSM-mec肽或其变体的存在表示耐甲氧西林金黄色葡萄球菌。 该变体优选是在单质子化状态下质量与电荷比为2415的PSM-mec肽的甲酰化形式。

公开(公告)号：WO2013118033A1

公开(公告)日：2013-08-15

申请号：PCT/IB2013/050812

申请日：2013-01-31

Applicant: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： LIU, Liang ,  LI, Ting ,  WONG, Kam Wai ,  JIANG, Zhihong ,  ZHOU, Hua

IPC: C12Q1/68 ,  A61K38/00 ,  A61K39/00 ,  A61P19/02 ,  A61P35/00 ,  A61P37/02

CPC classification number: G01N33/573 ,  A61K31/352 ,  A61K31/4188 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/102 ,  G01N2800/44

Abstract: Uses and applications derived from the discovery of a novel binding site of ΙΚΚ-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract translation: 提供了从发现IotaKappaKappa-β的新结合位点得到的用途和应用，例如筛选治疗剂作为治疗癌症，炎症或其它疾病/障碍的候选药物的方法。

公开(公告)号：WO2011163423A3

公开(公告)日：2013-07-25

申请号：PCT/US2011041537

申请日：2011-06-22

Applicant: UNIV CENTRAL FLORIDA RES FOUND ,  TURKSON JAMES

Inventor： TURKSON JAMES

IPC: A61K38/00 ,  C07H21/04 ,  C12N15/00 ,  C12P21/06

CPC classification number: C07K14/435 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4703 ,  C07K14/4705 ,  C07K16/18 ,  C07K16/3015 ,  G01N33/564 ,  G01N33/574 ,  G01N33/6893 ,  G01N2800/24 ,  G01N2800/44 ,  G01N2800/56

Abstract: Disclosed herein are compositions for inhibition of Stat, particularly Stat3. Disclosed herein are compositions comprising cell permeable Stat3 inhibitors. Compositions may comprise peptides, polypeptides, antibodies, nucleic acids, vectors, and host cells for making, using, assaying, and evaluating Stat3 inhibitors. Disclosed herein are methods for making and using the disclosed compositions.

Abstract translation: 本文公开了抑制Stat的组合物，特别是Stat3。 本文公开了包含细胞渗透性Stat3抑制剂的组合物。 组合物可以包括肽，多肽，抗体，核酸，载体和用于制备，使用，测定和评估Stat3抑制剂的宿主细胞。 本文公开了制备和使用所公开的组合物的方法。

公开(公告)号：WO2012122017A3

公开(公告)日：2012-11-01

申请号：PCT/US2012027477

申请日：2012-03-02

Applicant: UNIV CORNELL ,  UNIV ROCKEFELLER ,  ELEMENTO OLIVIER ,  KAPOOR TARUN M ,  WACKER SARAH A

Inventor： ELEMENTO OLIVIER ,  WACKER SARAH A

IPC: C12Q1/68

CPC classification number: G06F19/16 ,  C12Q1/6874 ,  G01N33/5008 ,  G01N2800/44

Abstract: A method of identification of drug targets and drug resistance mechanisms in human cells of a drug comprising the steps of: generating at least one drug-resistant sample and at least one drug-sensitive sample; analyzing substantial portions of the genome and/or transcriptome of the least one drug-resistant sample and drug-sensitive sample to obtain sequencing data; detecting substantially all alterations in the at least drug-resistant sample; deriving a resistance signature; and performing analysis of the drug resistance signature of at least one recurrently altered gene using bioinformatic tools and cellular biology methods to determine if alteration of the at least one gene of the drug resistance signature is sufficient to confer at least partial resistance to cells or tissues against the drug.

Abstract translation: 一种在药物人体细胞中鉴定药物靶标和耐药机制的方法，包括以下步骤：产生至少一种耐药样品和至少一种药物敏感样品; 分析至少一种药物抗性样品和药物敏感样品的基因组和/或转录组的大部分，以获得测序数据; 检测至少耐药性样品中的所有改变; 导出电阻签名; 以及使用生物信息学工具和细胞生物学方法进行至少一个循环改变的基因的耐药性特征的分析，以确定抗药性特征的至少一个基因的改变是否足以赋予对细胞或组织的至少部分抗性以抵抗 毒品。

公开(公告)号：WO2012097276A2

公开(公告)日：2012-07-19

申请号：PCT/US2012/021283

申请日：2012-01-13

Applicant: EXPRESSION PATHOLOGY, INC. ,  KRIZMAN, David, B. ,  HEMBROUGH, Todd ,  THYPARAMBIL, Sheeno ,  LIAO, Wei-li

Inventor： KRIZMAN, David, B. ,  HEMBROUGH, Todd ,  THYPARAMBIL, Sheeno ,  LIAO, Wei-li

IPC: C12Q1/37

CPC classification number: G01N33/6893 ,  C07K14/4747 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/76 ,  C12Q1/485 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5088 ,  G01N33/574 ,  G01N33/6848 ,  G01N2333/4703 ,  G01N2800/44 ,  G01N2800/52 ,  G01N2800/56

Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin- fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue™ reagents and protocol, and the BIM protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a BIM peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

Abstract translation: 提供了来自Bcl-2样蛋白11（BIM）的那些肽的特异性肽和衍生的电离特征，其特别有利于通过选择反应的方法在福尔马林中固定的生物样品中直接定量BIM蛋白 监测（SRM）质谱，或什么也可以称为多反应监测（MRM）。 在生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块）和 来自这些区块的细胞和已被福尔马林固定和石蜡包埋的组织培养细胞。 使用Liquid TissueTM试剂和方案从生物样品制备蛋白质样品，并且通过SRM / MRM质谱法通过在蛋白质样品中定量至少一种或多种的蛋白质样品，在Liquid TissueTM样品中定量BIM蛋白质 描述的肽。 如果它们以修饰或未修饰的形式存在，则可以定量这些肽。 BIM肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。

公开(公告)号：WO2011066504A1

公开(公告)日：2011-06-03

申请号：PCT/US2010/058198

申请日：2010-11-29

Applicant: PHYSICIANS REFERENCE LABORATORY, LLC ,  MANNA, Pradip

Inventor： MANNA, Pradip

IPC: G01N33/48 ,  C12Q1/68

CPC classification number: C12Q1/689 ,  C12Q2600/156 ,  G01N2800/44

Abstract: Provided are methods of detecting the presence and/or amount of methicillin-resistant S. aureus in a sample. The methods may include, in some embodiments, processing the sample with a lysyl endopeptidase followed by amplification and detection of S. aureus chromosomal DNA if present in the sample. The PCR amplification may include the use of one or more forward primers that target SCCmec right chromosomal junction regions, a reverse primer that targets an or fK region and at least one probe that targets and or fX region between the forward and reverse primers. The reverse primer and/or the at least one probe may be targeted to conserved regions of or fX , i.e. regions that do not contain SNPs or other polymorphisms. Sets of oligonucleotides and kits for performing the methods are also provided.

Abstract translation: 提供了检测样品中耐甲氧西林金黄色葡萄球菌的存在和/或量的方法。 在一些实施方案中，所述方法可以包括用赖氨酰内肽酶处理样品，然后如果存在于样品中，则扩增和检测金黄色葡萄球菌染色体DNA。 PCR扩增可以包括使用靶向SCCmec右染色体连接区的一个或多个正向引物，靶向orfK区的反向引物和至少一个靶向的前导引物和正向和反向引物之间的orfX区。 反向引物和/或至少一个探针可以靶向到orfX的保守区域，即不含有SNP或其他多态性的区域。 还提供了用于执行方法的一组寡核苷酸和试剂盒。

公开(公告)号：WO2010079158A1

公开(公告)日：2010-07-15

申请号：PCT/EP2010/050044

申请日：2010-01-05

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  FORGEZ, Patricia ,  GOMPEL, Anne

Inventor： FORGEZ, Patricia ,  GOMPEL, Anne

IPC: G01N33/574 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K51/085 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/726 ,  G01N2800/44 ,  G01N2800/52

Abstract: The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.

Abstract translation: 本发明涉及乳腺癌的治疗方法，预后评估和检测方法。

公开(公告)号：WO2008045344A8

公开(公告)日：2009-07-02

申请号：PCT/US2007021433

申请日：2007-10-05

Applicant: GEN HOSPITAL CORP ,  ELLISEN LEIF W ,  LEONG CHEE-ONN

Inventor： ELLISEN LEIF W ,  LEONG CHEE-ONN

IPC: G01N33/574

CPC classification number: G01N33/57415 ,  G01N2800/44

Abstract: The present invention relates, generally, to methods to identity subjects responsive to p73/p63 targeting agents such as platinum-based chemotherapy agents such as, but not limited to, cisplatin and cisplatin derivatives and analogues thereof. More particularly, the present invention relates to methods to identify a cancer responsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin, by determining if the cancer expresses and/or has the activity of p63 isoforms such as DNp63 isoforms, and expresses and/or has the activity of p73 isoforms such as TAp73 or DNp73 isoforms. The present invention also relates to methods to identify a cancer unresponsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin by determining if the cancer lacks the expression and/or activity of p63 isoforms such as DNp63 isoforms. The invention further provides kits to determine the expression and/or activity of p63 isoforms such as DNp63 isoforms, and/or the expression and/or activity of p73 isoforms such as TAp73 and/or DNp73 isoforms in a biological sample.

Abstract translation: 本发明一般涉及识别对p73 / p63靶向剂（如基于铂的化疗剂，例如但不限于顺铂和顺铂衍生物及其类似物）的p73 / p63靶向物响应的受试者的方法。 更具体地说，本发明涉及通过确定癌症是否表达和/或具有p63同种型如DNp63同种型的活性来鉴定响应于p73 / p63靶向治疗的癌症如化疗剂如顺铂的方法， 并表达和/或具有p73同种型如TAp73或DNp73同种型的活性。 本发明还涉及通过确定癌症是否缺乏p63同种型例如DNp63同种型的表达和/或活性来鉴定对p73 / p63靶向治疗无响应的癌症的方法，例如化疗剂如顺铂。 本发明进一步提供了确定p63同种型如DNp63同种型的表达和/或活性和/或生物样品中p73同种型如TAp73和/或DNp73同种型的表达和/或活性的试剂盒。